Metformin suppresses high glucose–induced poly(adenosine diphosphate–ribose) polymerase overactivation in aortic endothelial cells

• Published in: Metabolism, clinical and experimental clinical and experimental, 2009-04, Vol.58 (4), p.525-533
• Main Authors: Mahrouf-Yorgov, Meriem, Marie, Nicolas, Borderie, Didier, Djelidi, Raja, Bonnefont-Rousselot, Dominique, Legrand, Alain, Beaudeux, Jean-Louis, Peynet, Jacqueline
• Format: Article
• Language: English
• Subjects: Animals; Biological and medical sciences; Blotting, Western; Cattle; Cells, Cultured; Endocrinology & Metabolism; Endothelium, Vascular - cytology; Endothelium, Vascular - drug effects; Endothelium, Vascular - enzymology; Enzyme Activation; Feeding. Feeding behavior; Fluorescent Antibody Technique; Fundamental and applied biological sciences. Psychology; Glucose - administration & dosage; Hypoglycemic Agents - pharmacology; Life Sciences; Metformin - pharmacology; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases - metabolism; Vertebrates: anatomy and physiology, studies on body, several organs or systems
• ISSN: 0026-0495; 1532-8600
• DOI: 10.1016/j.metabol.2008.11.012

Abstract Overactivation of poly(adenosine diphosphate–ribose) polymerase (PARP), an enzyme involved in cellular response to DNA injury resulting from oxidative and nitrosative stress, is considered to play a key role in the pathogenesis of diabetes complications by promoting numerous vascular dysfunctions. In this study, we examined the ability of metformin, which was reported to possess intrinsic vasculoprotective properties independently of its antihyperglycemic effects, to inhibit PARP activation induced by high glucose concentrations in bovine aortic endothelial cells; and we investigated the potential mechanisms involved in this inhibition. The PARP activity was measured by cellular enzyme-linked immuno-specific assay (CELISA) method; cell poly(ribosyl)ated protein polymer accumulation was evaluated by immunofluorescence. Peroxynitrite anion productions were determined using dihydrorhodamine 123 fluoroprobe; and expression of p47phox subunit of nicotinamide adenine dinucleotide phosphate (NAD(P)H) oxidase was analyzed by Western blot in the absence and presence of protein kinase C and NAD(P)H oxidase inhibitors (calphostin and diphenyleneiodonium chloride, respectively). Our data showed that a therapeutically relevant concentration of metformin (5.10−5 mol/L) was able to abolish PARP activation, to reduce poly(ribosyl)ated protein polymer accumulation, to decrease intracellular peroxynitrite anion level, and to reverse the overexpression of p47phox in bovine aortic endothelial cells stimulated by 25 mmol/L glucose in a similar manner to that of calphostin or diphenyleneiodonium chloride. Taken together, these results suggest that metformin could inhibit glucose-induced PARP activation through blockade of a protein kinase C–dependent NAD(P)H oxidase activation pathway. We propose that some of the beneficial effects of metformin on vascular endothelial cell functions in diabetes may be related to its inhibitory effect on PARP overactivation and its deleterious consequences.